Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy.

This study will investigate the combination of Ytrium-90 (Y-90) Selective Internal Radiation Therapy (SIRT) followed by Stereotactic Body Radiation Therapy (SBRT). Y-90 SIRT alone or SBRT alone are standard procedures used in the treatment of liver cancer. This study will assess the combination of Y-90 SIRT and SBRT and obtain preliminary information about the side effects and safety of the combination therapy. Additionally, this is the first time that Y-90 PET-CT imaging will be included in planning for SBRT.

NCT Number	NCT04518748
Lead Sponsor	University of Michigan Rogel Cancer Center Collaborators: Department of Health and Human Services, National Institute for Biomedical Imaging and Bioengineering (NIBIB)
Conditions	Liver Malignancy
Enrollment	70 participants
Start Date	2020-09-16
Primary Completion	2028-05 (estimated)
Study Completion	2028-11 (estimated)
Updated on ClinicalTrials.gov	2026-07-31